Table 2.
Rosiglitazone alleviates intrahepatic cholestasis: Biochemical assay
|
Parameters |
Treatment | ||||
|---|---|---|---|---|---|
| Vehicle | Rosi | ANIT | ANIT + Rosi | ||
| LW/BW (%) | 4.30 ± 0.11 | 4.92 ± 0.06 | 5.91 ± 0.18* | 4.72 ± 0.32# | |
| BW (g) | 18.27 ± 0.51 | 18.20 ± 1.04 | 16.51 ± 1.36* | 16.72 ± 0.66 | |
| Serum enzyme activity, total bilirubin, and lipids | ALT | 27.2 ± 2.0 | 22.9 ± 0.68 | 1,749 ± 182* | 347 ± 81.8# |
| AST | 123.8 ± 2.5 | 117.8 ± 6.3 | 5,416 ± 626* | 956 ± 341.0# | |
| ALP | 129.3 ± 3.7 | 109.8 ± 3.5 | 383 ± 24.7* | 247.5 ± 6.4# | |
| γ‐GT | 1.27 ± 0.22 | 1.27 ± 0.12 | 21.54 ± 2.68* | 9.81 ± 1.40# | |
| TBIL | 0.26 ± 0.02 | 0.16 ± 0.01 | 22.16 ± 3.92* | 2.2 ± 0.63# | |
| T‐CHO | 2.66 ± 0.31 | 3.46 ± 0.13 | 7.10 ± 1.03* | 5.51 ± 0.21 | |
| LDL‐C | 0.44 ± 0.05 | 0.49 ± 0.02 | 2.09 ± 0.15* | 0.5 ± 0.10# | |
| HDL‐C | 1.95 ± 0.22 | 2.44 ± 0.80 | 0.98 ± 0.15* | 3.22 ± 0.23# | |
| TG | 0.58 ± 0.01 | 0.68 ± 0.04 | 3.43 ± 0.60* | 0.87 ± 0.07# | |
| Liver TBA | 0.73 ± 0.05 | 0.55 ± 0.09 | 2.52 ± 0.22* | 1.67 ± 0.34# | |
| Intestine TBA | 12.24 ± 0.81 | 17.85 ± 1.43 | 6.14 ± 0.94* | 19.34 ± 1.33# | |
Note. C57BL/6J mice received vehicle (corn oil), rosiglitazone (Rosi), α‐naphthylisothiocyanate (ANIT), or rosiglitazone plus α‐naphthylisothiocyanate (Rosi + ANIT) treatment as indicated in Figure 1a. After treatment, mouse bodyweight (BW) and liver weight (LW) were determined to calculate the ratio of LW/BW (%). Enzyme activity of ALT, AST, ALP, and γ‐GT (as U·L−1) and concentration of TBIL (μmol·L−1), T‐CHO, LDL‐C, HDL‐C, and TG (mmol·L−1) were measured in serum samples. Total bile acids (TBA, μmol) were determined in samples of liver and intestine.
*
P < .05, significantly different from Ctrl (vehicle) # P < .05, significantly different from ANIT (n = 5).